Solara Active Pharma Sciences

Solara Active Pharma Sciences

657.25
-39.75
(-5.70%)
ann
Q1 Quarterly Results are out. Check out the updated financials2 days ago
Viewcross
right
Market Cap
2,376.24 Cr
EPS
0.14
PE Ratio
102.63
Dividend Yield
0.00 %
Industry
Healthcare
52 Week High
882.80
52 Week Low
442.80
PB Ratio
2.31
Debt to Equity
0.83
Add Ratio
hide

Investment Returns

In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%

Company News

View All News
Caret
neutral
Solara Active Pharma Sciences Reports No Deviation in Rights Issue Fund Utilization for Quarter Ended June 30, 20253 days ago
Solara Active Pharma Sciences Limited confirmed no deviation in the utilization of funds raised through its Rights Issue for the quarter ended June 30, 2025. The company raised Rs. 149.49 crores on May 6, 2025, with funds allocated for repayment of borrowings (Rs. 115 crores) and general corporate purposes (Rs. 23.27 crores). Out of the total funds raised, Rs. 138.27 crores were utilized during the quarter, while Rs. 0.26 crores remained in the escrow account and Rs. 10.96 crores in the monitoring account for future utilization. The Rights Issue involved 1,19,98,755 partly paid Rights Shares at Rs. 131.25 per share, with CRISIL Ratings Limited serving as the monitoring agency. The company's Audit Committee reviewed and approved the utilization statement without any comments.
positive
Solara Active Pharma Reports Strong Q1 FY26 Results with 15% Revenue Growth and Positive Earnings3 days ago
Solara Active Pharma Sciences Limited reported quarterly results for the period ended June 30, 2025, showing revenue of Rs. 319.15 crores, up 15% quarter-on-quarter from Rs. 273.01 crores. The company achieved a profit of Rs. 10.52 crores compared to a loss of Rs. 13.46 crores in the same quarter last year. Gross margins improved to 54.1% from 44.5% year-on-year, while EBITDA margins reached 18.0% versus 11.6% in the previous year. The company reduced gross debt from Rs. 7,760 million to Rs. 6,327 million during the quarter. Earnings per share turned positive at Rs. 2.46 compared to a loss of Rs. 3.50 per share in the corresponding quarter. The Board also appointed Mr. Rajesh Patro as Chief Risk Officer. Regulated markets constituted 77% of total revenues, and the company expects to raise Rs. 134.99 crores through pending rights issue calls.
positive
Solara Active Pharma Sciences delivered improved quarterly results with EBITDA rising to 570 million rupees from 419 million rupees year-over-year. The company's EBITDA margin expanded significantly to 17.87% compared to 11.5% in the same period last year. The pharmaceutical company turned profitable with a consolidated net profit of 105 million rupees, marking a turnaround from a loss of 135 million rupees in the previous year. However, revenue declined to 3.2 billion rupees from 3.63 billion rupees year-over-year.
Competitors
LTP
Market Cap (₹ Cr.)
P/E Ratio
Revenue (₹ Cr.)
YoY Revenue Growth %
Net Profit (₹ Cr.)
YoY Profit Growth %
RSI
1,702.20
#1 4,08,414.80
35.57
#1 54,729.00
12.06
#1 10,980
-18.99
55.97
6,584.00
1,74,784.51
80.22
9,712.00
0.89
2,191
23.05
40.37
1,572.00
1,26,971.67
22.93
28,409.50
7.12
5,291
9.88
70.77
3,622.90
1,21,969.00
63.65
11,539.40
6.99
1,911
19.91
72.46
1,287.40
1,07,442.68
#1 18.77
33,741.20
16.73
5,725
1.26
54.50
2,541.60
1,04,899.14
61.83
12,744.20
19.57
2,007
-10.91
52.39
980.10
98,620.99
21.15
23,511.00
13.82
4,615
-0.19
54.96
1,960.50
89,535.15
27.44
22,909.50
#1 19.94
3,306
#1 112.49
53.75
32,895.00
69,899.58
50.72
6,684.70
10.80
1,414
27.83
42.22
1,127.00
65,456.34
18.86
31,378.10
17.55
3,366
-0.50
47.15

Automatic Screeners on ScanX

Forecast
Actual
Growth Rate
Revenue Growth
-11.74 %
Net Income Growth
2,442.60 %
Cash Flow Change
-30.32 %
ROE
3,990.54 %
ROCE
-1,472.62 %
EBITDA Margin (Avg.)
-165.04 %

Quarterly Financial Results

Quarterly Financials
Jun 2018
Sept 2018
Dec 2018
Mar 2019
Jun 2019
Sept 2019
Dec 2019
Mar 2020
Jun 2020
Sept 2020
Dec 2020
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Jun 2025
Revenue
303
344
360
392
335
356
350
309
353
404
435
454
412
405
105
367
337
342
402
385
354
426
212
301
364
347
302
279
320
Expenses
263
295
294
321
267
283
266
247
265
300
321
345
315
330
199
349
318
311
350
332
333
393
436
412
322
286
243
228
262
EBITDA
40
49
66
71
68
73
84
62
88
104
114
109
97
75
-94
18
20
31
52
53
21
34
-224
-111
43
62
59
51
58
Operating Profit %
13 %
14 %
17 %
17 %
19 %
19 %
23 %
17 %
24 %
25 %
25 %
22 %
22 %
18 %
-98 %
3 %
4 %
8 %
11 %
13 %
5 %
8 %
-106 %
-38 %
12 %
18 %
19 %
17 %
18 %
Depreciation
19
19
21
23
23
24
24
24
26
28
27
27
28
28
28
28
28
29
28
27
26
26
26
25
25
25
25
24
24
Interest
18
20
23
22
19
20
19
20
20
19
21
25
19
17
18
22
23
22
24
22
25
24
25
31
31
28
27
29
24
Profit Before Tax
3
9
22
26
27
29
41
18
42
57
66
57
50
30
-140
-31
-31
-19
1
5
-29
-17
-275
-167
-14
8
8
-2
11
Tax
0
1
0
0
0
0
0
0
0
0
0
0
0
0
0
-33
-15
-9
0
1
-10
0
0
89
0
0
0
0
0
Net Profit
3
9
22
26
27
29
41
18
42
57
66
57
50
30
-140
2
-17
-10
0
4
-19
-17
-275
-255
-14
8
8
-2
11
EPS in ₹
0.23
3.47
8.96
10.17
10.29
11.21
16.00
6.78
15.75
19.21
18.47
15.57
13.95
8.27
-38.93
0.53
-4.56
-2.77
0.12
1.05
-5.43
-4.77
-72.07
-70.93
-3.50
2.54
2.03
-0.93
2.46

Balance Sheet

Balance Sheet
2018
2019
2020
2021
2022
2023
2024
2025
Total Assets
1,822
1,960
2,154
2,614
2,945
2,899
2,351
2,232
Fixed Assets
1,086
1,218
1,397
1,382
1,356
1,364
1,268
1,109
Current Assets
608
648
672
1,058
1,239
1,188
801
729
Capital Work in Progress
72
40
41
88
239
239
256
280
Investments
1
0
0
0
0
2
2
318
Other Assets
663
702
716
1,144
1,350
1,295
825
0
Total Liabilities
1,822
1,960
2,154
2,614
2,945
2,899
2,351
2,232
Current Liabilities
738
656
730
789
1,063
1,101
1,243
944
Non Current Liabilities
315
344
333
232
354
296
172
191
Total Equity
769
960
1,090
1,593
1,527
1,502
937
1,094
Reserve & Surplus
739
826
963
1,553
1,489
1,464
898
1,054
Share Capital
25
26
27
36
36
36
36
40

Cash Flow

Cash Flow
2018
2019
2020
2021
2022
2023
2024
Net Cash Flow
32
30
-20
142
-151
-38
-0
Investing Activities
-86
-113
-359
-106
-243
-81
-4
Operating Activities
49
166
242
156
-242
156
109
Financing Activities
68
-23
97
93
334
-113
-106

Share Holding

% Holding
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Jun 2025
Promoter
44.11 %
41.07 %
41.07 %
39.51 %
39.71 %
40.40 %
40.40 %
40.40 %
40.97 %
39.31 %
37.19 %
30.49 %
30.49 %
37.27 %
37.27 %
37.23 %
37.94 %
42.01 %
FIIs
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
15.80 %
14.00 %
14.25 %
14.67 %
14.63 %
14.25 %
DIIs
3.72 %
6.18 %
5.55 %
5.38 %
3.39 %
2.85 %
2.56 %
3.01 %
2.22 %
1.75 %
1.75 %
1.71 %
2.97 %
2.83 %
3.38 %
3.19 %
2.61 %
2.62 %
Government
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
Public / Retail
14.76 %
14.35 %
13.84 %
16.36 %
17.41 %
16.61 %
17.28 %
16.54 %
16.23 %
18.06 %
19.84 %
20.95 %
20.15 %
19.61 %
18.83 %
21.93 %
23.07 %
23.47 %
Others
37.41 %
38.40 %
39.53 %
38.73 %
39.48 %
40.15 %
39.76 %
40.04 %
40.58 %
40.88 %
41.22 %
46.84 %
30.59 %
26.29 %
26.28 %
22.98 %
21.74 %
17.63 %
No of Share Holders
58,907
67,197
65,449
73,000
77,228
82,710
83,319
79,149
76,325
75,417
74,473
72,918
73,912
78,617
71,882
83,148
75,791
74,334

Dividend History

Dividends per share (FY)
Dividend yield (FY) %
Dividends per share (FY)
Dividend yield (FY) %
Annual Cash Flows 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Dividend Per Share (₹) 0.00 0.00 0.00 5 2 7 0.00 3 0.00 0.00
Dividend Yield (%) 0.00 0.00 0.00 1.22 0.16 1.14 0.00 0.88 0.00 0.00

Corporate Action

Record Date Corporate Action Information Announcement Day LTP at Annoucement LTP at Record Day
25 Jul 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
25 Jul 2025 692.85 657.35
15 May 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
15 May 2025 482.35 576.30
24 Jan 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
24 Jan 2025 652.85 678.80
21 Oct 2024 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
21 Oct 2024 748.90 809.60
20 Sept 2024 ANNUAL GENERAL MEETING Annual General Meeting
NA
20 Sept 2024 694.40 736.35
15 May 2024 RIGHTS Rights
1:3
15 May 2024 465.01 503.40
20 Aug 2021 DIVIDEND Dividend
₹ 3.00 /share
18 Aug 2021 1,484.58 1,564.11
25 Mar 2017 CHANGE OF NAME Change Of Name
NA
25 Mar 2017 0.00 0.00

Announcements

Announcement under Regulation 30 (LODR)-Newspaper Publication2 days ago
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome3 days ago
Announcement under Regulation 30 (LODR)-Press Release / Media Release3 days ago
Statement Of Deviation And Variation For Funds Raised Under Rights Issue For The Quarter Ended June 30 2025.3 days ago
Board Meeting Outcome For Unaudited Financial Results For The Quarter Ended June 30 2025.3 days ago
Board Meeting Outcome for Board Meeting Outcome For Unaudited Financial Results For The Quarter Ended June 30 2025.3 days ago
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation7 days ago
Board Meeting Intimation for Quarter Ended June 30 2025 Under SEBI Listing Regulations10 days ago
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jul 17, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationJul 07, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationJul 03, 2025
Dispatch Of First Reminder Notice For Payment Of First Call MoneyJul 02, 2025
Announcement under Regulation 30 (LODR)-Credit RatingJul 01, 2025
Closure of Trading WindowJun 27, 2025
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Jun 17, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 28, 2025
Compliances-Reg.24(A)-Annual Secretarial ComplianceMay 28, 2025
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptMay 21, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 16, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeMay 15, 2025
Appointment Of Internal Auditors Secretarial Auditor And Reappointment Of Cost Auditor.May 15, 2025
Appointment of Company Secretary and Compliance OfficerMay 15, 2025
Announcement under Regulation 30 (LODR)-RetirementMay 15, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementMay 15, 2025
Statement Of Deviation And VariationMay 15, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMay 15, 2025
Board Meeting Outcome for Audited Financial Results For The Quarter And Year Ended March 31 2025May 15, 2025
Audited Financial Results For The Quarter And Year Ended March 31 2025May 15, 2025
Announcement Under Regulation 30 - Press ReleaseMay 10, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 08, 2025
Board Meeting Intimation for Board Meeting IntimationMay 07, 2025
Announcement under Regulation 30 (LODR)-Monitoring Agency ReportMay 07, 2025
Board Meeting Outcome for Board Meeting Outcome For The Rights Issue Committee Meeting - Receipt Of First Call MoneyMay 06, 2025
Announcement under Regulation 30 (LODR)-Change in Corporate Office AddressMay 05, 2025
Announcement under Regulation 30 (LODR)-Change in Registered Office AddressMay 05, 2025
Incorporation Of Wholly Owned Subsidiary CompanyApr 29, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Apr 17, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationApr 09, 2025
Notice On The First Call Money Of The Rights Equity Shares.Apr 09, 2025
Board Meeting Outcome for Outcome Of The Rights Issue Committee Meeting_Solara Active Pharma Sciences LimitedApr 02, 2025
Announcement under Regulation 30 (LODR)-Meeting UpdatesApr 02, 2025
Board Meeting Intimation for Rights Issue Committee Meeting To Approve The Notice Of First Call To Be Sent To The Eligible Shareholders.Mar 26, 2025
Closure of Trading WindowMar 26, 2025
Record Date For The Purpose Of Making First Call For Rights Issue Equity SharesMar 26, 2025
Board Meeting Outcome for Intimation Under Regulation 30 And 42 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Mar 26, 2025
Announcement under Regulation 30 (LODR)-Meeting UpdatesMar 26, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationMar 21, 2025
Shareholder Meeting / Postal Ballot-Notice of Postal BallotMar 20, 2025
Board Meeting Intimation for Rights Issue Committee Meeting For Making The First Call Of The Shares Issued On Rights Basis By The Company.Mar 20, 2025
Grant Of ESOP OptionsFeb 21, 2025

Technical Indicators

RSI(14)
Neutral
56.12
ATR(14)
Volatile
33.83
STOCH(9,6)
Neutral
55.17
STOCH RSI(14)
Oversold
16.32
MACD(12,26)
Bearish
-4.43
ADX(14)
Very Strong Trend
54.74
UO(9)
Bearish
40.79
ROC(12)
Uptrend But Slowing Down
4.63
WillR(14)
Neutral
-63.37

Mutual Fund Holdings